Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis). (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - Approximately 1 hour. (en)
|
http://linked.open...ugbank/indication
| - Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. (en)
|
http://linked.open.../drugbank/synonym
| - Cephotaxime (en)
- Cefotaxim (en)
- (6R,7R,Z)-3-(Acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (en)
- Cefotaxima (en)
- Cefotaximum (en)
- CĂ©fotaxime (en)
- (6R,7R)-3-(Acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (en)
- (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (en)
|
http://linked.open...drugbank/toxicity
| - Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD<sub>50</sub> is over 20,000 mg/kg while intravenous rat LD<sub>50</sub> is over 7,000 mg/kg. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open.../drugbank/mixture
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Ingolf Macher, Gerhard Widschwenter, "Production of cefotaxime and new sodium salts." U.S. Patent US5831086, issued May, 1992. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Rapidly absorbed following intramuscular injection. (en)
|
http://linked.open.../affectedOrganism
| - Enteric bacteria and other eubacteria (en)
- Neisseria meningitidis (en)
- Escherichia coli (en)
- Haemophilus influenzae (en)
- Neisseria gonorrhoeae (en)
- Salmonella typhi (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |